Last reviewed · How we verify
Live attenuated HAV vaccine
This vaccine contains live attenuated (weakened) hepatitis A virus that stimulates the immune system to produce antibodies and cellular immunity against hepatitis A without causing disease.
This vaccine contains live attenuated (weakened) hepatitis A virus that stimulates the immune system to produce antibodies and cellular immunity against hepatitis A without causing disease. Used for Prevention of hepatitis A infection in susceptible individuals.
At a glance
| Generic name | Live attenuated HAV vaccine |
|---|---|
| Also known as | Live attenuated hepatitis A vaccines |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine uses a genetically weakened strain of hepatitis A virus that replicates in the body but does not cause clinical hepatitis. This replication triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protection against wild-type hepatitis A infection. The attenuated virus is sufficiently weakened to be safe while maintaining immunogenicity.
Approved indications
- Prevention of hepatitis A infection in susceptible individuals
Common side effects
- Injection site pain or erythema
- Fever
- Fatigue
- Headache
Key clinical trials
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
- Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV (PHASE3)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live attenuated HAV vaccine CI brief — competitive landscape report
- Live attenuated HAV vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI